Stock screener

CCCC

Conviction 85HealthcareScan · Mon, Aug 10, 2026
CCCC$3.61-3.22%
ResistanceSupportVol 14
63 bars
Vol MA14 2.6M
May 11May 28Jun 16Jul 6Jul 23Aug 10
C4 Therapeutics, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.c4therapeutics.com
Price3.61
Change-3.22%
Gap+0.00%
Rel volume1.95×
Avg volume2.81M
Avg $ vol10.2M
SMA 203.63
SMA 503.92
SMA 2002.90
Price vs 50-7.94%
Price vs 200+24.65%
MA stackmixed
50/200 cross
Supertrenddown · 4.23
RSI (14)46
MACD hist0.01
MACD crossbull · 2d
Stoch %K / %D42 / 51
ADX (14)15
+DI / −DI16 / 18
RSI divergence
MACD divergence
ATR %+6.54%
ADR %5.79%
52w high4.67
52w low1.71
From 52w high-22.70%
Above 52w low+111.11%
New 52w highNo
SqueezeOn · 4d
Bollinger width12.24%
%B0.46
Donchian pos40.98%
Donchian high3.97
Donchian low3.36
AVWAP (52w high)3.89
vs AVWAP high-7.25%
AVWAP (52w low)3.40
vs AVWAP low+6.17%
OBV trendDown
Chaikin MF (20)-0.05
Today vs 20d1.95×
Avg vol (14d)2.6M
Avg vol (20d)2.81M
Avg $ vol (20d)10.2M
Market cap399.15M
RS 3m (vs SPY)+19.47%
RS 6m (vs SPY)+104.01%
RS line new highNo
Trend template7/8
Technical rank62.6
1 week+3.14%
1 month-11.08%
3 months+22.37%
6 months+98.35%
1 year+39.92%
YTD+87.05%
P/E-3.80
P/B1.70
P/S11.10
P/FCF-4.02
EPS-1.27
Div yield
ROE-44.82%
ROA-31.93%
Debt/Eq0.00
Current9.00
EV/EBITDA
Gross margin
Net margin-292.08%
Rev growth1.02%
EPS growth0.31%
Price target8.50
Target upside135.46%
Analyst ratingBuy
Institutional89.72%
Ent. value337.87M
Revenue6.15M
Net income-25.13M
Gross profit
Free cash flow-99.3M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out110.57M
Employees104
ListedFri, Oct 2, 2020
Free float75.13M
Float %77.5%
Short interest23.82M
Days to cover6.7d
Short volume42.4%
Squeeze score81 / 100
Next earnings
EPS forecast
Last EPS vs est−$0.20 vs −$0.21
Last surprise+4.8% beat
Setup gradeA+
Conviction85 / 100
Pattern quality
Tech rank62.6 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction
Pattern family
Resistance4.83
Support3.38
Days since event
Candle confirm
News sentiment

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in CCCC

All disclosures →
No recent disclosed trades by Congress in CCCC. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in CCCC · 9 buys · 1 sell

InsiderSideShares
REYNO LEONARD
Chief Medical Officer · Common Stock · 2026-07-10
Exercise15.32K
REYNO LEONARD
Chief Medical Officer · Common Stock · 2026-07-10
Tax7.4K
GROGAN DONNA ROY
Director · Stock Option (Right to Buy) · 2026-06-24
Grant62K
Fawell Stephen
Director · Stock Option (Right to Buy) · 2026-06-24
Grant62K
Cooper Ronald Harold Wilfred
Director · Stock Option (Right to Buy) · 2026-06-24
Grant62K
Hoerter Steven L.
Director · Stock Option (Right to Buy) · 2026-06-24
Grant62K
Hughes Owen
Director · Stock Option (Right to Buy) · 2026-06-24
Grant62K
Anderson Kenneth Carl
Director · Stock Option (Right to Buy) · 2026-06-24
Grant62K
Bessen Laura
Director · Stock Option (Right to Buy) · 2026-06-24
Grant62K
Koppikar Utpal
Director · Stock Option (Right to Buy) · 2026-06-24
Grant62K

SEC filings

EDGAR filings in CCCC · 3 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.